Evidence map›Paper›PMID 32368861›Full record

ArticleJournal of cellular and molecular medicine2020

The proteasome activator PA200 regulates expression of genes involved in cell survival upon selective mitochondrial inhibition in neuroblastoma cells.

Abdennour Douida, Frank Batista, Agnieszka Robaszkiewicz, Pal Boto, Azzam Aladdin, Mónika Szenykiv, Rita Czinege, László Virág, Krisztina Tar

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Abdennour DouidaDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Frank BatistaDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Agnieszka RobaszkiewiczDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Pal BotoStem Cell Differentiation Laboratory, Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary.
Azzam AladdinDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Mónika SzenykivDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Rita CzinegeDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
László VirágDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Krisztina TarDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.ORCID 0000-0002-1810-0128
University of Debrecen · HUUniversity of Łódź · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conserved Blm10/PA200 activators bind to the proteasome core and facilitate peptide and protein turnover. Blm10/PA200 proteins enhance proteasome peptidase activity and accelerate the degradation of unstructured proteasome substrates. Our knowledge about the exact role of PA200 in diseased cells, however, is still limited. Here, we show that stable knockdown of PA200 leads to a significantly elevated number of cells in S phase after treatment with the ATP synthase inhibitor, oligomycin. However, following exposure to the complex I inhibitor rotenone, more PA200-depleted cells were in sub-G1 and G2/M phases indicative of apoptosis. Chromatin immunoprecipitation (ChIP) and ChIP-seq data analysis of collected reads indicate PA200-enriched regions in the genome of SH-SY5Y. We found that PA200 protein peaks were in the vicinity of transcription start sites. Gene ontology annotation revealed that genes whose promoters were enriched upon anti-PA200 ChIP contribute to the regulation of crucial intracellular processes, including proliferation, protein modifications and metabolism. Selective mitochondrial inhibitors induced PA200 redistribution in the genome, leading to protein withdrawal from some gene promoters and binding to others. Collectively, the results support a model in which PA200 potentially regulates cellular homeostasis at the transcriptional level, in addition to its described role as an alternative activator of the proteasome.

Indexed as

Gene Expression Regulation, NeoplasticApoptosisCell CycleCell DeathCell Line, TumorCell SurvivalChromatinHumansMitochondriaNeuroblastomaNuclear ProteinsOligomycinsReproducibility of ResultsRotenoneChromatinNuclear ProteinsOligomycinsPSME4 protein, humanRotenonecell deathcell viabilitymitochondrial inhibitorsneuroblastomapromoter bindingproteasome activator PA200

Identifiers

PMID32368861
PMCPMC7299700
OpenAlexW3023358679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.